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Macrophages are phagocytic cells involved in the immune response. They are derived 
from circulating monocytes which differentiate into macrophages in the tissues. Despite small 
phenotypic variations due to the different microenvironments of the tissues, all macrophages act 
as the first line of defense against invading pathogens. 1 
Macrophages primarily combat infection as a key component of innate immunity. They 
are involved in both the initiation and maintenance of the inflammatory response, as well as the 
initiation of the adaptive immune response. 1' 15 In innate immunity, macrophages establish the 
inflammatory response. 1 Specifically, these cells phagocytose bound pathogens to destroy them 
in phagolysosomes, and produce compounds, such as nitric oxide (NO) and reactive oxygen 
intermediates (ROS), to aid in destruction of pathogens. Macrophages also produce and secrete 
pro-inflammatory cytokines after being activated. Release of cytokines such as tumor necrosis 
factor-a (TNF) or interleukin-6 (IL-6) enhances activation of phagocytes through autocrine and 
paracrine signaling, and promotes recruitment of additional leukocytes to the site of infection. 
TNF is also capable of directly killing extracellular microbes. 1' 12' 17 Through these innate immune 
response activities the macrophages generally resist further replication of the pathogen and 
reduce the total number of pathogens in the body.3 
Before a macrophage can perform these immune functions, it must be activated. 
Activation may occur via binding of pro-inflammatory cytokines to cell surface receptors or by 
recognition of pathogen-associated molecular patterns (P AMPs ). Lipopolysaccharide (LPS), a 
component of gram-negative bacterial cell walls, is a common macrophage activating PAMP. 
LPS binds to CD 14 and Toll-like Receptor 4 (TLR4) on the macrophage surface, stimulating a 
cascade that results in the phosphorylation and subsequent degradation of cytosolic IKB. NF-KB 
is thus released from IKB to enter the cell nucleus, and promote the transcription of pro-
inflammatory genes. In response to the LPS signaling pathway, NF-KB promotes the 
transcription of inducible nitric oxide synthase (iNOS), superoxide-producing enzymes and pro-
inflammatory cytokines to combat the infection. 1'3'9' 12 Other P AMPs stimulate additional 
signaling cascades to activate transcription factors to start production of anti-microbial genes. 1•3 
Catecholamines are small monoamines, such as NE which has been shown to be released 
by the sympathetic nervous system during stress responses. 5•15•19 Although catecholamines are 
predominantly derived from the neuroendocrine system, recent work has shown that NE and 
dopamine are also synthesized by activated macrophages. 2,4 Catecholamines mediate their effects 
by binding to the adrenergic receptors expressed on macrophages. Adrenergic receptors are 
seven-transmembrane G-protein coupled receptors with cytoplasmic tails that interact with Gs 
proteins. The activation of Gs proteins initiates signaling cascades that alter the immunological 
activity level of activated macrophages in response to PAMPs. Primarily, stimulation of ARs 
induces changes in NO and cytokine production correlating with the identity and concentration 
of catecholamine to which the macrophages were exposed. 5•15•19 
1 
Adrenergic receptors can be divided into two major subgroups: a-AR and P-AR. 
Generally, treatment of LPS-activated macrophages with P-ARs agonists has been demonstrated 
to significantly reduce NO and inflammatory cytokine production. 14•17 This effect can be 
abrogated by the addition of P-AR antagonists, indicating that the decrease is specific to 
stimulation of the P-AR signaling cascade by catecholamines. 4 Kizaki et al. indicates that this 
decrease in immunological activity is due to reduced release of NF-KB from IKB in the treated 
macrophage's cytoplasm, preventing transcription of pro-inflammatory genes. 11 
However, a small but significant body of primary literature has shown that stimulation of 
the P-ARs of activated macrophages increases their immunological activity. A study by Szelenyi 
et al. showed that treatment with isoproterenol, a P-AR agonist, increased TNF production by 
macrophages activated with phorbol myristyl acetate.17 It has also been demonstrated that the 
enhancing effect of NE on macrophage production of NO can be abrogated by the addition of 
propranolol, a P-AR antagonist. 3 
There is also some disagreement in the primary literature regarding the role of a-ARs in 
regards to regulating immunological activity of activated macrophages. In general, treatment 
with a-AR agonists has been demonstrated to enhance the functions of activated macrophages. 
Stimulation of a-ARs by clonidine during Mycobacterium avium or Toxoplasma gondii 
infections significantly increases macrophage resistance to pathogen growth.6•19 Likewise, UK-
14304 (an a-AR agonist) and low concentrations of NE have been shown to enhance TNF 
production. This effect appears to be mediated at the transcriptional level, as increases in TNF 
mRNA are seen in activated macrophages treated with NE. Antagonism of a-ARs with 
yohimbine has been shown to significantly decrease the production ofTNF in response to a-AR 
stimulation with a constant level of agonist, suggesting that the enhancement is mediated 
exclusively by stimulation of the a-ARs. 9•15 However, another study found that stimulation of a-
ARs with NE suppressed phagocytosis by macrophages. 7 Clonidine treatment has also been 
shown to have no effect on NO production by activated macrophages, leading to the hypothesis 
that a-ARs do not play a regulatory role in macrophages. 14 The discrepancies in these results 
clearly point to a need to increase understanding of the role of a-AR signaling in macrophages. 
Previous studies have generally demonstrated a distinctive pattern of regulation of 
primary macrophages by adrenergic receptor stimulation. However, a complete characterization 
of the regulation of RA W264.7 murine macrophages, an important cell culture model, has yet to 
be performed. Additionally, a small but significant subset of current primary literature 
contradicts the generally-accepted model of AR-mediated regulation of macrophages. These 
functional differences may be due to changes in AR surface expression patterns in response to 
LPS activation and/or stimulation by catecholamines, but little analyses has been performed in 
this area. Therefore, further study is necessary to elucidate the roles and expression patters of 
AR h d . . IOJJ s on macrop ages urmg an immune response. · 
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In this study, AR surface expression patterns and regulation via AR-catecholamine 
interactions were characterized. Macrophage function was shown to be regulated by 
catecholamines through both a- and ~-ARs, as evidenced by corresponding alterations in 
cytokine production. Treatment of activated macrophages with NE, a general catecholamine, or 
fomoterol, a P-AR agonist, produced significant decreases in TNF and IL-6 secretion. The effecis 
of clonidine, an a-AR agonist, produced less consistent results, but clonidine-mediated 
enhancement of cytokine secretion appears to be mediated by a-AR signaling. LPS was shown to 
noticeably change the surface expression ofboth types of ARs in RAW264.7 macrophages. 
However, NE only influenced a-AR signaling. This data adds to the current model of 
neuroendocrine regulation of macrophage-mediated immunity, specifically presenting functional 
roles for a- and P-ARs. 
Materials and Methods 
RA W264. 7 Cell Culture 
The RA W264. 7 murine macrophage cell line was used to model macrophage activity. 
Cells were stored in liquid nitrogen until needed. After thawing, RA W264.7 macrophages were 
cultured in RPMI-1640 complete media supplemented with 10% heat-inactivated fetal calf 
serum, 1.5% sodium bicarbonate, 25 mM HEPES buffer, 1 % minimal essential medium 
vitamins, 1 % glutamine, 1 % nonessential amino acids, I 00 units/ml penicillin, and I 00 µg/ml 
streptomycin. Cells were maintained in T25-cm2 or T75-cm2 tissue culture flasks in a humidified 
incubator at 37°C, 5% CO2• Fresh media was added and cells were sub-cultured as needed to 
maintain health. 
Sandwich Enzyme-Linked Immunosorbent Assays 
RA W264.7 murine macrophage cells were cultured to confluency in T75-cm2 flasks. For 
experiments, cells were seeded into the wells of a 12-well tissue culture plate at a density of 1.5 
x I 06 cells per well. Macrophages were treated with 5 µM, 2.5 µM, 500nM and 50nM clonidine, 
or 1 µM, 500nM, 1 00nM and I 0nM fomoterol (FOM), or I µM, 500nM, 1 00nM and 1 0nM NE. 
Additional studies were performed by treating cells treated with RS79948 (500 nM), an a-
adrenergic receptor antagonist, for 30minutes (3 7°C, 5% CO2) prior to the addition of 5 µM, 2.5 µM, 
500nM or 50nM clonidine. Control wells were left untreated and unactivated. All treatment 
groups were then incubated for 30 minutes (37°C, 5% CO2) before 30 ng/ml or 10 ng/ml LPS 
was added to the media to activate the macrophages. The cells were incubated (37°C, 5% CO2) 
for the appropriate times (TNF studies: 4 hours; IL-6 studies: 21 hours), then supematants were 
harvested from each well and centrifuged at 11,000 rpm for 5 minutes. The pelleted debris was 
discarded, and clean microfuge tubes of supernatants were frozen at -20°C until analysis. 
An OptEIA Mouse TNF-a enzyme-linked immunosorbent assay (ELISA) kit (BD 
Biosciences) was used to measure the quantity ofTNF secreted by each treatment group. The 
ELISA was performed according to the manufacturer's instructions. A 96-well microtiter plate 
was coated with 1:250 dilution ofTNF Capture Antibody, and incubated overnight at 4°C. The 
wells were then washed three times with lx Wash Buffer, and blocked with Assay Diluent for 1 
3 
hour at room temperature. The wells were washed three times after the incubation. An aliquot of 
each sample was added to wells in triplicate, and a standard curve of purified TNF (1000 pg/ml 
to 15.6 pg/ml) was generated. The plate was incubated for 2 hours at room temperature, and then 
washed five times. A 1 :250 dilution of TNF Detection Antibody was added to each well for 1 
hour at room temperature. After washing the wells five times, a 1 :250 dilution of Streptavidin-
HRP secondary antibody was added to the wells. After a 30 minute incubation, the wells were 
washed seven times with a 30-60 second soak in lx Wash Buffer between each wash. TMB 
substrate was then added to each well, and the microtiter plate was incubated in the dark for 30 
minutes. Stop solution was added to the wells, and the microtiter plate was read with a plate 
reader at 450 nm with a correction reading at 570 nm. TNF concentrations in each treatment 
group were calculated according to the absorbencies of the TNF standard curve. 
An OptEIA Mouse IL-6 ELISA kit (BD Biosciences) was used to quantify the amount of 
IL-6 secreted by each treatment group. This kit followed the same protocol as the TNF-a ELISA 
Kit with a few notable changes. All antibodies used were specific for the IL-6 cytokine, and the 
standard curve was prepared using dilutions of purified IL-6 (1000 pg/ml to 15.6 pg/ml). 
Additionally, the Detection Antibody and Strepavidin-HRP were added in the same step. 
Statistical Analysis 
Concentrations ofTNF and IL-6 were calculated from their respective standard curves. 
An ANOVA with a Tukey's Analysis using a p<0.05 was used to calculate significant changes 
between sample treatments. All statistical analyses were performed with Graph Pad Prism 
software. 
Jmmunohistochemistry 
RA W264.7 macrophages were cultured to confluency as previously described. Equal 
quantities of cells were plated onto sterile cover slips placed in the wells of a 12-well tissue 
culture plate. The cells were incubated (37°C, 5% CO2) for 2-4 hours, then non-adherent cells 
were removed by washing with lx PBS. Some experimental samples were treated with 1 µM NE, 
and incubated for 30 minutes at 37°C, 5% CO2• All experimental samples were activated with 
100 ng/ml LPS. Control samples were not treated or activated. After a 4 hour incubation (37°C, 
5% CO2) cells were fixed with glyoxal (37°C, 15 minutes). Media was removed with three 
washes using lx PBS, and cover slips were moved into a clean 12-well plate. The cells were then 
blocked with a solution of 1 % powdered milk in lx PBS for 30 minutes at room temperature 
with gentle swirling. The cells were then washed three times, and incubated with either 1 :25 
mouse anti-a 28 adrenergic receptor antibody (Santa Cruz Biotechnology, Inc., sc-1479 or 1:50 
mouse anti-~ 2 adrenergic receptor antibody (Santa Cruz Biotechnology, Inc., sc-570) in blocking 
solution for 30 minutes at room temperature. After three more washes, a 1: 100 dilution of anti-
mouse AlexaFluor 594 or 647 secondary antibody (Invitrogen) in blocking solution was added to 
the corresponding wells. After a 30 minute incubation in the dark, the cover slips were washed 
4 
three times. The cover slips were mounted on slides using Prolong Gold Anti-Fade Mounting 
Medium, and stored overnight at 4°C. Slides were sealed with nail polish and stored in the dark 
at 4°C until analyzed. Samples with no antibodies, only primary antibody, only secondary 
antibody, or serum with secondary antibody were prepared as controls to demonstrate the 
specificity of tlw antibodies used. 
Confocal Microscopy 
Slides were viewed using a Leica SP2 Laser Scanning Confocal Microscope, at excitation 
wavelengths of 561nm and 633nm for AlexaFluor 594 and 647 samples, respectively. Emission 
was collected from 600 to 670nm for samples with AlexaFluor 594, and 650 to 750nm for 
AlexaFluor 64 7. Gain and offset were set to the same levels for all collected images. Transmitted 
light images were also collected from the confocal microscope. Leica Confocal Software was 
used to collect images, and figures were prepared with Adobe Photoshop CS3. 
Results 
Treatment with high concentrations of NE reduces TNF secretion by RA W264. 7 macrophages 
Macrophages produce pro-inflammatory cytokines to protect the host from bacterial 
infections. The secretion of these inflammatory mediators is tightly regulated, such that 
cytokines are only secreted in response to recognition of an on-going infection. This secretion 
can be used in studies as a measure correlating to overall immunological activity level of 
activated macrophages. 1 The secretion of cytokines has also been shown to be regulated by 
signaling via ARs in activated macrophages, and can thus be used as a measure of the effects of 
catecholamine treatment. 3' 14' 17 
To study the ability of catecholamines to regulate macrophage function, we examined the 
effect of treatment with the catecholamine NE on TNF production by activated RA W264. 7 
macrophages. A sandwich ELISA was used to measure the amount ofTNF produced by the 
LPS-activated macrophages pre-treated with NE. Analysis demonstrated that activation with LPS 
elicits dose-dependent secretion ofTNF from RA W264.7 macrophages. At both concentrations 
ofLPS, pre-treatment with lµM or 500 nM NE results in a significant decrease in the amount of 
TNF secreted. Macrophages activated with 30 ng/ml LPS still show a significant decrease in 
TNF secretion when treated with 100 nM NE, but the same NE concentration in the presence of 
10 ng/ml LPS does not alter TNF secretion from baseline levels. At either LPS concentration, 
addition of 10 nM NE has no effect on the production ofTNF by activated macrophages (Figure 
1). As NE is known to bind both a- and P-ARs, it was expected that treatment would alter 
cytokine secretion. 16 The reduction of TNF levels in response to treatment with high 
concentrations of NE suggests that the P-AR signaling cascade was strongly activated. However, 
low concentrations of NE did not alter TNF production so these studies do not provide evidence 
for a-AR expression or function on RA W264.7 macrophages. Given these results, further 
5 
research was needed to study the expression pattern of both types of ARs on RA W264.7 
macrophages. 
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Figure 1. Concentrations of TNF produced in response to NE treatment of activated RA W264.7 macrophages. 
RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106 cells/well. Cells were 
then treated with 1 µM, 500 nM, 100 nM or 10 nM NE for 30 minutes and then activated with 30 ng/ml or 10 ng/ml 
LPS. Cells were incubated for 4 hours (37°C, 5%CO2) before supernatants were harvested. The concentration of 
TNF in each sample was quantified using a TNF sandwich ELISA. Statistical analysis was performed using Graph 
Pad Prism software. 
Treatment with the /J-adrenergic receptor agonist fomoterol reduces cytokine secretion by 
RA W264. 7 macrophages 
The inhibitory effect of NE on TNF production is known to be mediated by stimulation 
of P-ARs on RA W264. 7 macrophages. 3 To better understand the role of P-ARs in macrophage 
activity, the macrophages were exposed to the specific P-AR agonist fomoterol (FOM) prior to 
macrophage activation. After a 4 or 21 hour incubation period, TNF and IL-6 secretion, 
respectively, was measured using an ELISA specific to each cytokine. ELISA analysis showed 
that treatment with FOM significantly reduces the amount of both IL-6 and TNF secreted (Figure 
2). A trend toward dose-dependent inhibition of IL-6 secretion is apparent from these studies 
(Figure 2A and 2B). However, secreted IL-6 levels do not return to baseline levels at 10 pM 
FOM, indicating that even extremely low concentrations of the P-AR agonist have a strong 
negative effect (Figure 2B). These dose-dependent changes are only seen when RA W264.7 
macrophages are activated with 30ng/ml LPS. When the cells are activated with 1 Ong/ml LPS, 
all the tested concentrations of FOM resulted in significantly decreased levels of secreted IL-6 
(Figure 2A and B). Figure 2C demonstrates that FOM also effectively reduces TNF levels 
produced by activated macrophages. Since FOM is known to selectively activate P-ARs, it can 
be concluded that the cytokine decreases are due to catecholamine-mediated signaling through 
the P-AR pathway. 
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Figure 2. Concentrations of IL-6 and TNF produced in response to FOM treatment of activated RA W264. 7 
macrophages. RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106 
cells/well. Cells were then treated with FOM (10 nM FOM - 10 pM) for 30 minutes and then activated with 30 
ng/ml or 10 ng/ml LPS. Cells were incubated (37°C, 5%CO2) for 21 hours prior to IL-6 ELISA analysis (A and B); 
or 4 hours prior to TNF ELISA analysis (C). Statistical analysis was performed using Graph Pad Prism software. 
Treatment with the a-adrenergic receptor agonist clonidine tends to enhance cytokine secretion 
by RA W264. 7 macrophages 
Primary macrophages also express a-ARs, which are generally believed to enhance the 
activity of activated macrophages. 6'9' 15' 19 However, a small portion of primary literature has also 
suggested that stimulation of the a-AR may have no effect on or decrease macrophage 
activity. 7' 14 To attempt to address this discrepancy in the literature, and to characterize the role of 
a-ARs in regulating the function of RA W264.7 macrophages during an immune response, we 
analyzed the production of TNF and IL-6 by LPS-activated macrophages treated with clonidine, 
an a-AR agonist. 
Macrophages were exposed to the specific a-AR agonist clonidine prior to macrophage 
activation. After a 4 or 21 hour incubation period, TNF and IL-6 secretion, respectively, were 
measured using an ELISA specific to each cytokine. Analysis of the ELISA data revealed that 
clonidine stimulates increases in IL-6 production at specific concentrations. A dramatic 
enhancement ofIL-6 secretion was seen when RA W264.7 macrophages were treated with 500 
nM clonidine. This effect was found when the macrophages were activated with either 
concentration ofLPS (30 ng/ml or 10 ng/ml). Additionally, macrophages activated with 10 ng/ml 
7 
LPS also showed a small but significant increase in IL-6 secretion in response to treatment with 
50 nM clonidine (Figure 3A). 
The effects of clonidine treatment on TNF secretion were less clear. Analysis of the 
ELISA data indicated that TNF secretion is sometimes enhanced, while in other treatments it is 
reduced or unaffected. Similar results were found with several repeated studies (Figure 3B). 
Although signaling via the a-AR pathway typically induces a stimulatory effect, a few studies 
have found that a-agonists can also negatively influence macrophage activity.7•14 Further 
research is necessary to determine what factors may influence the ambivalent behavior of a-AR 
signaling. 
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Figure 3. Concentrations of IL-6 and TNF secreted in response to clonidine treatment of activated RA W264. 7 
macrophages. RA W264.7 macrophages were plated into 12-well tissue culture plates at a density of 1.5 x 106 
cells/well. Cells were treated with 5 µM, 2.5 µM, 500 nM or 50 nM clonidine for 30 minutes and then activated with 
30 ng/ml or 10 ng/ml LPS. Cells were incubated (37°C, 5%CO2) for 21 hours prior to IL-6 ELISA analysis (A); or 4 
hours prior to TNF ELISA analysis (B). Statistical analysis was performed using Graph Pad Prism software. 
Treatment with the a-adrenergic receptor antagonist RS79948 inhibits the enhancement of 
cytokine production seen in clonidine-treated, LPS-activated RA W264. 7 macrophages 
In an effort to further characterize the role of a-ARs in the regulation of macrophage 
immunological activity, RAW264.7 macrophages were treated with RS79948, an a-AR 
antagonist, prior to treatment with clonidine. The addition of RS79948 blocks any signaling 
through a-ARs, and thus abrogates any effects which are mediated by a-AR signaling. 
ELISA analysis demonstrated that treatment of activated macrophages with 500 nM or 50 
nM clonidine increases the concentration of cytokine secreted by the activated RA W264.7 cells 
(Figures 3 and 4). The addition of RS79948 prior to clonidine treatment results in a significant 
decrease in IL-6 production, returning the amount of secreted cytokine to levels equivalent to or 
below those measured in untreated, activated macrophages (Figure 4A). Likewise, TNF secretion 
is significantly impacted by blocking the a-AR pathway. RS79948 antagonism of the a-AR 
pathway significantly decreases the amount of TNF secreted from the activated macrophages to 
below positive control levels (Figure 4B). These results suggest that the positive effect of 
8 
clonidine is mediated by signaling through the a-AR pathway, as blocking the stimulation of a-
ARs abrogates this effect. Furthermore, the observation that cytokine levels decrease below that 
of positive controls suggests that a-AR signaling may normally be involved in enhancing 
macrophage activity in response to LPS activation. 
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Figure 4. Concentrations ofIL-6 and TNF secreted in response to treatment of activated macrophages with clonidine 
and the a-AR antagonist RS79948. RA W264. 7 macrophages were plated into 12-well tissue culture plates at a 
density of 1.5 x 106 cells/well. Cells were then treated with 500 nM or 50 nM clonidine after a 30 minute incubation 
with RS79948 and then activated with 10 ng/ml LPS. Cells were incubated (37°C, 5%CO2) for 21 hours prior to IL-
6 ELISA analysis (A); or 4 hours prior to TNF ELISA analysis (B). Statistical analysis was performed using Graph 
Pad Prism software. 
Regulation of surface expression of /3-adrenergic receptors by LPS activation and NE exposure 
In addition to studying the functional role of ARs, studies were also performed to 
characterize the expression pattern of ARs on RA W264.7 macrophages. These 
immunofluorescence studies were performed with mouse anti-P-AR primary antibody and anti-
mouse IgG-AlexaFluor 594 conjugated secondary antibody. All labeled macrophages were 
examined with a confocal microscope. Appropriate controls were also included to demonstrate 
that each antibody was specific to its indicated protein, and to control for autofluorescence of the 
RA W264.7 macrophages (data not shown). 
Immunofluorescence reveals a distinctive pattern of P-AR surface expression in 
RA W264.7 macrophages. Resting macrophages exhibit high levels of surface P-ARs (Figure 5 
Al-A2'). However, the expression noticeably decreases in activated macrophages, as these 
images are characterized by reduced staining intensity and less overall staining (Figure 5 B 1-
B2 '). NE treatment of activated macrophages does not visibly alter P-AR expression from the 
reduced levels seen in activated macrophages (Figure C l-C2 '). These results suggest a 
mechanism of cross-talk between pathways which regulates P-AR expression in response to 
recognition of extracellular LPS. 11 
9 
Figure 5. Surface expression of P-ARs by RA W264.7 macrophage in response to LPS activation and NE treatment. 
RA W264. 7 macrophages were plated in wells containing sterile glass coverslips. Cells were treated with l µM NE, 
then activated with 100 ng/ml LPS and incubated for 4 hours. Mouse anti-P-AR antibody was used as primary 
antibody, and anti-mouse IgG-AlexaFluor conjugated antibody was used as the secondary antibody. 
Immunofluorescence images were collected using Leica Confocal Software with a Leica SP2 Laser Scanning 
Confocal Microscope, and the contrast in transmitted light images was enhanced u ing Adobe Photoshop CS3 
Extended software. Red images (Al-C2) were obtained using anti-mouse IgG secondary antibody conjugated with 
AlexaF\uor 647; Green images (Al '-C2') were obtained using anti-mouse IgG secondary antibody conjugated with 
AlexaFluor 594. Al A2 A I ' A2' represent resting RA W264.7 macrophages ; BI, B2, Bl ', B2' represent 
RA W264.7 macrophages activated with I00ng/ml LPS; Cl, C2, Cl', C2' represent RAW264.7 macrophages 
activated with I00ng/ml LPS and treated with lµM NE 
Regulation of urface expression of a-adrenergic receptor. by LPS activation and NE expo ure 
Studies were also performed to characterize the surface expression of a,-ARs in response 
to LPS activation and E exposure. Immunofluorescence was performed using mouse anti-u-AR 
primary antibody and anti-mouse TgG-AlexaFluor594 conjugated secondary antibody . All 
images were collected using confocal microscopy. Controls were again performed to 
demonstrate that the antibodies used were specific to their advertised epitopes and to control for 
autofluorescence of the RA W264.7 cells (data not shown). 
Immunofluorescence reveals that quiescent RA W264.7 macrophages express extremely 
low levels of o.-ARs on their surface. This pattern is characterized by very low intensity staining, 
and widely dispersed points of fluorescence (Figure 6 Al-2). Activation with LPS noticeably 
increases the intensity of surface staining, as well as the number of points emitting fluorescence. 
This indicates that activated macrophages increase the expression of a,-ARs on their surfaces 
(Figure 6 B 1- B2). Treatment with E appears to result in a slight decrease in the amount and 
10 
intensity of fluorescence, indicating a slight decrease in a-AR expression (Figure 6 Cl-2). 
However, more quantitative immunofluorescence studies are needed to determine if this apparent 
change represents a significant decline. 
Most images are collected at the surface of the cells to best demonstrate visible changes 
in AR expression. Optical sectioning through the center of a cell reveals a distinctive ring of 
fluorescence around the perimeter of a cell, and that staining is generally specific to the plasma 
membrane of RA W264.7 macrophages. This indicates that changes seen in the 
immunofluorescence studies reflect changes in surface protein expression, rather than global 
changes in protein expression throughout the cell (Figure 6 D1-2). 
Figure 6. Surface expression of <I-ARs by RA W264.7 macrophages in response to LPS activation and NE treatment. 
RA W264 .7 macrophages were plated in wells containing sterile glass coverslips . Cells were treated with lµM NE, 
then activated with I 00 ng/ml LPS and incubated for 4 hours. Mouse anti-<I-AR antibody was used as primary 
antibody, and anti-mouse IgG-AlexaFluor 594 conjugated antibody was used as the secondary antibody. 
Immunofluorescence images were collected using Leica Confocal Software with a Leica SP2 Laser Scanning 
Confocal Microscope , and the contrast in transmitted light images was enhanced using Adobe Photoshop CS3 
Extended software. Al , A2 represent resting macrophages ; B 1, B2 represent RA W264 .7 macrophages activated 
with 100 ng/ml LPS; Cl , C2, D 1, D2, represent RA W264. 7 macrophages activated with I 00 ng/ml LPS and treated 
with lµMNE. 
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Discussion 
This study was designed to characterize the expression patterns of a- and i1-ARs, and the 
role they play in regulating RA W264. 7 macrophage activity. This cell line is commonly used as 
a model of macrophage behavior, but much of the research regarding catecholamine-mediated 
regulation of macrophages has been performed with primary macrophages. Given the relevance 
of RA W264. 7 macrophages as a model, it is important to understand their regulation. This data 
indicates that signaling through the P-AR decreases macrophage function, and it is thus in 
agreement with most previous studies. 3•11•14•17•18 Cytokine secretion, a common measure used to 
represent the immunological activity level of macrophages, was significantly decreased after 
treatment with NE or FOM, a P-AR agonist. B-ARs are also strongly expressed in quiescent 
macrophages, and their surface expression decreases in response to LPS activation of the 
macrophages. 
Conversely, a-AR surface expression is extremely low in quiescent macrophages, but 
noticeably increases after LPS activation. NE treatment also appears to slightly decrease a-AR 
surface expression on activated macrophages. While the changes in surface expression of a-ARs 
appear relatively straightforward, the role of a-ARs in regulating macrophage immunological 
activity has yet to be fully characterized. This research suggests that enhancement of cytokine 
secretion by catecholamines is mediated through a-ARs, as antagonizing the receptors abrogated 
this effect. However, TNF studies exhibited both an enhancement and a decline in cytokine 
secretion after treatment with the a-AR agonist. These results suggest that changes in a-AR 
surface expression may alter the regulation of cytokine secretion. Additionally, some changes in 
expression may be due to conditions that have yet to be clearly defined. 
Macrophages are cellular mediators of innate immunity, and play an essential role in 
maintaining health. To carry out this function, macrophages must be capable ofresponding to 
PAMPs displayed in MHCs and free in the extracellular matrix. Additionally, the body must 
carefully regulate these cells to avoid over-activity or excessive suppression, both of which can 
result in disease states. 1 Recent research has demonstrated that macrophages are regulated by 
direct immunological signals as well as neuroendocrine signaling via catecholamines. 
Catecholamines regulate inflammatory response behavior in macrophages by binding to surface 
ARs, initiating signaling cascades that are hypothesized to alter macrophage function. Current 
research indicates that stimulation of these two ARs tends to have different, if not opposite, 
effects on macrophages. 15 In this study, strong evidence was found to support a negative effect 
on immunological activity by the ~-AR stimulation. However, the role of the a-AR remains more 
elusive. 
In the body, NE can bind to both a- and P-ARs to alter immunological function of 
macrophages. The preference for one type of AR over the other has been shown to be 
concentration dependent, with high concentrations of NE inducing a predominantly P-AR effect. 
The results shown here support this model, as decreases in TNF secretion were seen as a result of 
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NE treatment (Figure 1). However, at very low concentrations, NE binds predominantly to the 
higher affinity a-AR and can enhance immunological function. 3•15•16•18 Epinephrine treatment 
similarly produces a predominantly f3-AR response, enhancing the production of anti-
inflammatory cytokines such as IL-10 as well as down-regulating pro-inflammatory cytokine 
production in LPS-activated primary macrophages. 13•18 
Kizaki et al. recently proposed a model detailing the cross-talk between the TLR4/LPS 
pathway and the P-AR pathway. Their study demonstrated that stimulation of P2-ARs decreases 
the degradation oflKBa in the cytoplasm of macrophages. This effect is mediated by a direct 
interaction between IKBa and P-arrestin 2, a protein that is activated by the f32-AR signaling 
cascade. This interaction stabilizes IKBa, and thus prevents the release of NF-KB from the 
complex. Lower NF-KB release ultimately results in lower levels of this transcription factor in 
the nucleus, and less transcription of pro-inflammatory genes in response to the TLR4 activation 
signal. 11 The results of these ELISA studies with the P-AR agonist FOM strongly support the 
model that J3-AR stimulation decreases cytokine release. According to the model proposed by 
Kazaki et al. it would appear that this decrease is a result of decreased transcription of cytokine 
genes. 11 However, further study is necessary to conclusively show that decreases in secreted 
cytokine concentrations are a result of transcriptional regulation. 
The immunofluorescence data which details surface expression of P-ARs offers a 
possible explanation for how the body may minimize the influence of P-ARs on macrophage 
function during an infection. High levels of P-ARs are expressed on the surface of resting 
RA W264.7 macrophages, and that surface expression decreases in response to LPS activation 
(Figure 5). Down-regulation of P-AR expression reduces the quantity of negative signals that can 
be sent to the macrophage. With fewer P-ARs expressed, less signal will be sent and thus less P-
arrestin 2 will be activated. This will allow for the degradation oflKBa, releasing more NF-KB to 
enter the nucleus of activated RA W264. 7 macrophages. Higher levels of pro-inflammatory genes 
will then to be produced, leading to a more efficient response to infection. 11 Down regulation of 
P-ARs would also thus prevent attenuation of the immune response before the pathogen is 
completely cleared from the organism. Additionally, signaling through P-ARs might be a 
mechani~m to reduce the level of TNF secretion that causes serious injury during acute sepsis. 18 
These studies help to explain how f3-ARs influence macrophage regulation, as well as a potential 
reason for this pattern of regulation, but further research is needed to understand the mechanism 
regulating expression of J3-ARs. 
Immunofluorescence images studying the a-AR also suggest a potential functional 
explanation for the documented expression pattern of a-ARs when combined with the current 
model of catecholamine effects on macrophage function. 6•19 Resting macrophages express very 
low levels of a-ARs on their surfaces, which may be a mechanism for preventing improper 
activation of the macrophages. Previous work with macrophages is in agreement with these 
results. RT-PCR studies demonstrate that resting macrophages express a 1-AR transcripts at 
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undetectable levels, but that transcripts then become detectable after activation with LPS.10 These 
low levels, coupled with the high level of ~-AR expression, might be maintained to ensure that 
any catecholamines present will signal predominantly through ~-ARs when no pathogen is 
present and the macrophages have not been activated, ensuring that the macrophages remain 
inactive. When macrophages become activated, there is a noticeable increase in a-AR 
expression. This increase alters the balance between a- and ~-ARs, increasing the likelihood of 
catecholamines binding to a-ARs. This change in expression may function as a mechanism to 
establish a positive feedback loop. \Vith higher expression of a-ARs, more stimulatory signals 
will be sent to the macrophage. This may result in a subsequent enhancement of macrophage 
function, and increased efficiency of pathogen clearance. 19 
Treatment with NE appears to induce a slight decrease in surface expression of a-ARs. 
As NE predominantly signals through ~-ARs, this suggests that there may be some cross-talk 
occurring between the two AR pathways that regulates the expression of the a-AR. 1s However, 
previous studies with THP-1 monocytes have shown that treatment with a ~2-AR agonist 
enhances the amount of a 1-AR transcript in the monocytes. 1° Further study is therefore necessary 
to identify the pathway involved in this cross-talk, and to determine its outcome. Current work is 
also continuing with characterizing a-AR expression through flow cytometry and western 
immunoblotting analysis. As with the ~-AR, additional studies are needed to fully understand 
how a-AR surface expression changes in response to exposure to pathogens (LPS activation) and 
exposure to catecholamines. 
The majority of studies have found that stimulation of a-ARs enhances immunological 
activity of macrophages. 6' 1s,I 9 Spengler et al. showed that treatment ofLPS-activated 
macrophages with UK-14304, a different a-AR agonist, resulted in an increase in TNF mRNA 
levels and secreted TNF levels. 1s Treatment with the a-AR antagonist yohimbine suppresses the 
normal increase in iNOS expression, and thus NO production, in macrophages activated with 
LPS. This indicates that the enhancing effects are a direct result of stimulation of a-ARs. 8 The 
results of our studies demonstrate an increase in IL-6 production after a-AR stimulation, in 
agreement with these previous studies showing that a-AR signaling enhances macrophage 
function. However, not all of our results support the conclusion that stimulation of the a-AR 
enhances cytokine secretion. Specifically, the production of TNF was reduced by activated 
macrophages after exposure to the a-AR agonist clonidine. Likewise, some previous studies have 
found that stimulation of a-ARs is not involved in enhancing cytokine production or, in some 
cases, actually decreases macrophage function.7•14 
These variable results may be explained by differences in the expression patterns of a-AR 
sub-types on the surface of macrophages during an immune response (LPS activation). Previous 
work has shown that macrophages express a 1- and a 2-ARs, and that only stimulation of a 2-ARs 
enhances macrophage immunological function.6•19 However, these sub-types have some 
overlapping agonist affinities, and stimulation of both sub-types may contribute to the variable 
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results since clonidine is a general a-AR agonist. 10 Additionally, macrophage a2-ARs have also 
been shown to have both high and low affinity catecholamine binding sites. Similar sites on 
neutrophils have been shown to initiate different signaling cascades when bound. At high 
concentrations the agonist binds to the low affinity site, while at lower concentrations 
(approximately 1 nM) the agonist binds to the high affinity site. The intermediate concentrations 
of clonidine used for these experiments may be stimulating both sites, and producing inconsistent 
cytokine secretion. Alternatively, high concentrations of clonidine have been shown to lead to 
non-specific binding to other surface receptors. Non-specific binding by clonidine to the ~-AR 
may also explain the measured decreases in TNF secretion. 15 Further study elucidating the 
signaling pathways initiated by a-AR stimulation might provide a better understanding of the a-
AR signaling pathway in macrophages. 
Despite these inconsistencies, studies with the a-AR antagonist RS79948 indicate that the 
stimulatory effects of clonidine are a result of signaling through the a-AR pathway, as addition 
of the antagonist abrogated this effect. Measurements of cytokine secretion show that addition of 
the antagonist reduced both TNF and IL-6 levels to below that of RA W264.7 macrophages 
treated only with LPS (Figure 4). A similar decrease in IL-I~ secretion to below baseline levels 
was seen when LPS-activated macrophages were treated with the a-AR antagonist yohimbine in 
previous studies.4 Previous work has shown that macrophages produce the catecholamines NE 
and epinephrine in response to LPS treatment. This suggests that these macrophage-derived 
catecholamines may act in an autocrine manner to further enhance inflammatory functions 
through a-AR signaling in the macrophage. Loss of this autocrine signaling by antagonism of a-
ARs thus results in lower levels of cytokine production than those measured for RA W264. 7 
macrophages treated with just LPS due to the loss of the positive feedback loop. Alternatively, 
autocrine signaling with the macrophage-produced cytokines may also decrease the 
inflammatory response via signaling through exclusively ~-ARs, as the a-ARs are blocked by the 
antagonist. 2' 15 
The results of this study support the current model that neuroendocrine signaling plays an 
essential role in regulating immune function. This regulation has been shown to be the result of 
interactions between catecholamines and the ARs expressed on the surface of macrophages. It 
appears that the sympathetic nervous system can enhance immune function through a-ARs. 19 
However, as NE is shown to have a predominately negative effect on cytokine secretion, it 
appears more likely that neuroendocrine signaling acts as an additional signal to reduce the 
strength of the immune response to protect the host from excessive damage. 18 With more 
research, the regulatory power of macrophage-expressed ARs may be used therapeutically to 
artificially enhance or shut down the immune system. 
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